May 16, 2022, Shanghai – Abbisko Therapeutics (Stock Code:  02256 and “Abbisko” hereafter) today announced the appointment of Dr. Zidong Zhang as Chief Financial Officer (“CFO”). He will report to Dr. Yao-Chang Xu, Chairman and CEO of Abbisko. 

Prior to Abbisko, Dr. Zhang served as CFO at Novotech Health Holdings, overseeing all aspects of financial management. He also previously served as CFO for Henlius Biotech where he built and managed the finance team and played a crucial role in the company’s initial public offering in 2019. Prior to that, Dr. Zhang was an equity research analyst at UBS in New York, covering the Large Cap and Specialty Pharmaceutical Sector. He also served as senior consultant for Bayer A.G. in its healthcare group. Before entering the industry, Dr. Zhang conducted his postdoctoral research in diabetes-related drug discovery at Boston University.

Dr. Zhang obtained his Ph.D. in BioChemistry from Boston University, MBA from Duke University and B.S. degree in Chemistry from Fudan University. 

“We are pleased to have Dr. Zhang join Abbisko to start the next stage of his career.” said Dr. Yao-Chang Xu, “Dr. Zhang brings to us rich experience in both the pharmaceutical and financial industry. His impressive record of executive management and expertise in finance and healthcare will be a valuable contribution to Abbisko’s journey to fulfill our strategic goals.”

“It is an honor to join Abbisko.” Dr. Zhang said, "I am greatly impressed with the highly diversified and innovative pipeline of Abbisko as well as its fully integrated drug discovery engine. I look forward to collaborating with such a dedicated team to bring innovative therapies to patients through the power of technology.”